BioVersys AG Cash Flow Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-21.83	-18.72	-18.3
Depreciation & Amortization	0.3	0.28	0.27
Loss (Gain) From Sale of Investments	-	-	0.21
Stock-Based Compensation	0.66	1.86	1.72
Other Operating Activities	1.87	0.45	0.72
Change in Accounts Payable	2.69	-2.8	4.8
Change in Other Net Operating Assets	-5.63	3.36	-1.08
Operating Cash Flow	-21.95	-15.57	-11.66
Capital Expenditures	-0.22	-0.04	-0.05
Investment in Securities	6	-2	3.34
Investing Cash Flow	5.78	-2.04	3.29
Long-Term Debt Issued	6.93	-	7.38
Long-Term Debt Repaid	-4.26	-0.25	-0.25
Net Debt Issued (Repaid)	2.67	-0.25	7.13
Issuance of Common Stock	76.84	14.71	0.02
Other Financing Activities	-6.94	4.73	-0.02
Financing Cash Flow	72.58	19.19	7.13
Foreign Exchange Rate Adjustments	-0.53	0.66	-0.95
Net Cash Flow	55.89	2.24	-2.19
Free Cash Flow	-22.16	-15.61	-11.7
Free Cash Flow Margin	-698.02%	-1287.06%	-1027.57%
Free Cash Flow Per Share	-3.95	-4.68	-3.92
Cash Interest Paid	0.04	0.08	0.02
Levered Free Cash Flow	-15.86	-9.46	-
Unlevered Free Cash Flow	-15.18	-8.82	-
Change in Working Capital	-2.95	0.56	3.72

Source: S&P Global Market Intelligence. Standard template. Financial Sources.